SR59230A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SR59230A 是一种有效、选择性、可穿透血脑屏障的 β3-肾上腺素受体拮抗剂，对 β3、β1 和 β2 受体的 IC50 值分别为 40、408 和 648 nM。

MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA.

SR59230A (100 nM-50 μM; 24 hours) is able to reduce cell viability in a dose-dependent manner in Neuro-2A, BE(2)C and SK-N-BE(2) NB cell lines. Cell Viability Assay Cell Line:Three different neuroblastoma (NB) cell lines, one murine (Neuro-2A) and two human (SK-N-BE(2), BE(2)C)Concentration:100 nM, 1 μM, 5 μM, 10 μM, and 50 μM Incubation Time:24 hours Result:Reduced cell viability in a dose-dependent manner, with significant effect at a concentration limit over 1?μM for Neuro-2A cells and 5?μM for SK-N-BE(2) and BE(2)C).

MDMA (20 mg/kg) produces a slowly developing hyperthermia, reaching a maximum increase of 1.8°C at 130 min post injection. SR59230A (0.5 mg/kg) produces a small but significant attenuation of the slowly developing hyperthermia to MDMA. SR59230A (5 mg/kg) reveals a significant and marked early hypothermic reaction to MDMA. Animal Model:Male C-57BL6J wild-type mice (22-35 g)Dosage:0.5 or 5 mg/kg Administration:Injected s.c.; administered 30 min prior to the injection s.c. of MDMA (20 mg/kg).Result:Modulated the actions of MDMA on temperature involve α1-adrenoceptor antagonism.

——

Angiogenesis

Adrenergic Receptor

——

——

——

174689-39-5

415.48

C??H??NO?

>98% (HPLC)

DMSO : 31.25 mg/mL (75.21 mM; Need ultrasonic)

O[C@@H](CN[C@H]1CCCC2=C1C=CC=C2)COC3=CC=CC=C3CC.O=C(O)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years